[{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCL12","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4 ant","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"GenFleet Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Motixafortide","moa":"CXCR4 ant","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ GenFleet Therapeutics","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ GenFleet Therapeutics"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Motixafortide","moa":"CXCR4","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Collaboration","leadProduct":"Motixafortide","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ Washington University School of Medicine","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Washington University School of Medicine"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Gloria Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Licensing Agreement","leadProduct":"Motixafortide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0.28000000000000003,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Gloria Biosciences","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ Gloria Biosciences"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"ISRAEL","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"Motixafortide","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ Not Applicable"},{"orgOrder":0,"company":"BioLineRx","sponsor":"JonesTrading Institutional Services","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Public Offering","leadProduct":"Motixafortide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ JonesTrading Institutional Services","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ JonesTrading Institutional Services"},{"orgOrder":0,"company":"BioLineRx","sponsor":"BlackRock","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Motixafortide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"BioLineRx \/ BlackRock","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ BlackRock"},{"orgOrder":0,"company":"BioLineRx","sponsor":"St. Jude Children's Research Hospital","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Motixafortide","moa":"","graph1":"Hematology","graph2":"Phase I","graph3":"BioLineRx","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"","sponsorNew":"BioLineRx \/ St. Jude Children's Research Hospital","highestDevelopmentStatusID":"6","companyTruncated":"BioLineRx \/ St. Jude Children's Research Hospital"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Ayrmid","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Licensing Agreement","leadProduct":"Motixafortide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BioLineRx","amount2":0.10000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BioLineRx \/ Ayrmid","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ Ayrmid"},{"orgOrder":0,"company":"BioLineRx","sponsor":"Highbridge Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Motixafortide","moa":"","graph1":"Technology","graph2":"Approved","graph3":"BioLineRx","amount2":0.01,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"BioLineRx \/ Highbridge Capital Management","highestDevelopmentStatusID":"12","companyTruncated":"BioLineRx \/ Highbridge Capital Management"}]
Find Clinical Drug Pipeline Developments & Deals for Motixafortide
Details :
BioLineRx granted Ayrmid an exclusive license to develop and commercialize Aphexda (motixafortide) across all indications, excluding solid tumor indications, and in all territories other than Asia.
Details :
The agreement aims to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with sickle cell disease (SCD).
Details :
The net proceeds will be used to advance the commercialization of APHEXDA (motixafortide) approved in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma.
Details :
BioLineRx plans to use proceeds for the commercialization of APHEXDA (motixafortide) in the U.S. for stem cell mobilization in multiple myeloma patients.
Details :
BL-8040 (motixafortide) is a CXCR4 inhibitor, which is being evaluated in combination with cemiplimab, and standard of care chemotherapies for the treatment of Pancreatic ductal adenocarcinoma.
Details :
BioLineRx initiated Phase I clinical trial studies evaluating BL-8040 (motixafortide), CXCR4/SDF-1 inhibitor, as monotherapy and in combination with natalizumab for the treatment of sickle cell disease.
Details :
Under the agreement, BioLineRx gain the rights for the development of Aphexda (motixafortide), a CXCR4 antagonist, in stem cell mobilization and pancreatic cancer, in Asia.
Details :
Aphexda (motixafortide) is a CXCR4 antagonist , which is investigated in combination with gemcitabine and nab-paclitaxel, versus gemcitabine and nab-paclitaxel alone, in first-line pancreatic cancers.
Details :
APHEXDA (motixafortide) is a CXCR4 antagonist , which is investigated in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma.
Reset All
